



(12) **United States Patent**  
**Olschewski et al.**

(10) **Patent No.:** **US 9,339,507 B2**  
(45) **Date of Patent:** **May 17, 2016**

(54) **TREPROSTINIL ADMINISTRATION BY INHALATION**  
(75) Inventors: **Horst Olschewski**, Graz (AT); **Robert Roscigno**, Chapel Hill, NC (US); **Lewis J. Rubin**, LaJolla, CA (US); **Thomas Schmehl**, Giessen (DE); **Werner Seeger**, Giessen (DE); **Carl Sterritt**, Weybridge (GB); **Robert Voswinckel**, Giessen (DE)

(73) Assignee: **United Therapeutics Corporation**, Silver Spring, MD (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 301 days.

(21) Appl. No.: **13/469,854**

(22) Filed: **May 11, 2012**

(65) **Prior Publication Data**  
US 2012/0216801 A1 Aug. 30, 2012

**Related U.S. Application Data**  
(60) Division of application No. 12/591,200, filed on Nov. 12, 2009, which is a continuation of application No. 11/748,205, filed on May 14, 2007.  
(60) Provisional application No. 60/800,016, filed on May 15, 2006.

(51) **Int. Cl.**  
**A61K 31/192** (2006.01)  
**A61P 9/12** (2006.01)  
**A61M 11/00** (2006.01)  
**A61K 31/557** (2006.01)  
**A61K 9/00** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **A61K 31/557** (2013.01); **A61K 9/008** (2013.01); **A61K 9/0078** (2013.01)

(58) **Field of Classification Search**  
CPC ..... **A61K 31/557**; **A61K 9/008**  
USPC ..... **514/569**  
See application file for complete search history.

(56) **References Cited**  
U.S. PATENT DOCUMENTS

- 3,664,337 A 5/1972 Lindsey et al.
- 4,001,650 A 1/1977 Romain
- 4,281,113 A 7/1981 Axen et al.
- 4,306,075 A 12/1981 Aristoff
- 4,306,076 A 12/1981 Nelson
- 4,349,689 A 9/1982 Aristoff
- 4,473,296 A 9/1984 Shofner et al.
- 4,486,598 A 12/1984 Aristoff
- 4,495,944 A 1/1985 Brisson et al.
- 4,635,647 A 1/1987 Choksi
- 4,668,814 A 5/1987 Aristoff
- 4,677,975 A 7/1987 Edgar et al.
- 4,683,330 A 7/1987 Aristoff

- 4,976,259 A 12/1990 Higson et al.
- 4,984,158 A 1/1991 Hillsman
- 5,063,922 A 11/1991 Hakkinen
- 5,080,093 A 1/1992 Raabe et al.
- 5,153,222 A 10/1992 Tadepalli et al.
- 5,234,953 A 8/1993 Crow et al.
- 5,322,057 A 6/1994 Raabe et al.
- 5,361,989 A 11/1994 Merchat et al.
- 5,363,842 A 11/1994 Mishelevich et al.
- 5,497,763 A 3/1996 Lloyd et al.
- 5,551,416 A 9/1996 Stimpson et al.
- 5,727,542 A 3/1998 King
- 5,865,171 A 2/1999 Cinquin
- 5,881,715 A 3/1999 Shibasaki
- 5,908,158 A 6/1999 Cheiman
- 6,054,486 A 4/2000 Crow et al.
- 6,123,068 A 9/2000 Lloyd et al.
- 6,357,671 B1 3/2002 Cewers
- 6,521,212 B1 2/2003 Cloutier et al.
- 6,626,843 B2 9/2003 Hillsman
- 6,756,033 B2 6/2004 Cloutier et al.
- 6,765,117 B2 7/2004 Moriarty et al.
- 6,803,386 B2 10/2004 Shorr et al.
- 6,809,223 B2 10/2004 Moriarty et al.
- 7,172,557 B1 2/2007 Parker
- 7,199,157 B2 4/2007 Wade et al.
- 7,384,978 B2 6/2008 Phares et al.
- 7,417,070 B2 8/2008 Phares et al.
- 7,544,713 B2 6/2009 Phares et al.
- 7,726,303 B2 6/2010 Tyvoll et al.
- 2003/0192532 A1 10/2003 Hopkins
- 2004/0063912 A1 4/2004 Blumberg et al.
- 2004/0105819 A1 6/2004 Hale et al.
- 2004/0149282 A1 8/2004 Hickie
- 2004/0265238 A1 12/2004 Chaudry
- 2005/0165111 A1 7/2005 Wade et al.
- 2005/0166913 A1 8/2005 Sexton et al.
- 2005/0183719 A1 8/2005 Wuttke et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

AU 1999959533 B2 2/2000  
DE 19838711 C1 6/2000

(Continued)

**OTHER PUBLICATIONS**

EPA Integrated Risk Information System (IRIS): data sheet for 3-methylphenol (m-cresol). Accessed at <http://www.epa.gov/iris/subst/0301.htm> on Mar. 9, 2014.\*

(Continued)

*Primary Examiner* — Jeffrey S Lundgren  
*Assistant Examiner* — Sara E Townsley  
(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP

(57) **ABSTRACT**

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.



(56)

## References Cited

## U.S. PATENT DOCUMENTS

2005/0282901	A1	12/2005	Phares et al.
2006/0147520	A1	7/2006	Ruegg
2006/0201500	A1	9/2006	Von Hollen et al.
2008/0200449	A1	8/2008	Olschewski et al.
2008/0280986	A1	11/2008	Wade et al.
2009/0036465	A1	2/2009	Roscigno et al.
2010/0076083	A1	3/2010	Olschewski et al.
2010/0236545	A1	9/2010	Kern
2010/0282622	A1	11/2010	Phares
2012/0177693	A1	7/2012	Cipolla et al.

## FOREIGN PATENT DOCUMENTS

DE	19934582	A1	1/2001
FR	2783431	A1	3/2000
JP	2003-522003	A	7/2003
WO	WO 01/58514	A1	8/2001
WO	WO 01/85241	A1	11/2001

## OTHER PUBLICATIONS

- Abe et al., "Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension," *J. Cardiovascular Pharmacology*, 2001, 37, 239-251.
- Aradigm Corporation news release Oct. 24, 2005, "Aradigm and United Therapeutics Sign Development and Commercialization Agreement Targeting Pulmonary Hypertension," Red Orbit News, <http://www.redorbit.com/modules/news/tools.php?tool=print&id=281787>, 2 pages.
- Aristoff et al., "Synthesis of benzopyran prostaglandins, potent stable prostacyclin analogs, via an intermolecular Mitsunobu reaction," *Tetrahedron Letters*, 1984, 25(36):3955-3958.
- Bein et al., "Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system," *J. Cardiovascular Pharmacology*, 1996, 27, 583-586.
- Benedict et al., "Evidence-based pharmacologic management of pulmonary arterial hypertension," *Clinical Therapeutics*, 2007, 29, 2134-2153.
- Bindl et al., "Aerosolized prostacyclin for pulmonary hypertension in neonates," *Archives of disease in childhood, Fetal and neonatal edition*, 1994, 71(3), F214-6.
- Booke et al., "Prostaglandins in Patients with Pulmonary Hypertension: The Route of Administration," *Anesth. Analg.*, 1998, 86:917, Letter to the Editor.
- Byron, Peter R., "Drug Delivery Devices, Issues in Drug Development," *Proc. Am. Thorac. Soc.*, 2004, 1:321-328.
- Channick et al., "Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension," *J. American College of Cardiology*, 2006, 48, 1433-1437.
- Doyle et al., "Inhaled prostacyclin as a selective pulmonary vasodilator," *Anaesthesia and Intensive Care*, Aug. 1996, 24(4):514-515.
- Dumas et al., "Hypoxic pulmonary vasoconstriction," *General Pharmacology*, 1999, 33, 289-297.
- Dworetz et al., "Survival of infants with persistent pulmonary hypertension without extracorporeal membrane oxygenation," *Pediatrics*, 1989, 84, 1-6.
- Ewert et al., "Aerosolized iloprost for primary pulmonary hypertension," *New England Journal of Medicine*, 2000, 343, 1421-1422.
- Ewert et al., "Iloprost als inhalative bzw. Intravenose langzeitbehandlung von patienten mit primärer pulmonaler hypertonie," *Z. Kardiol.*, 2000, 89, 987-999.
- Fink et al., "Use of Prostacyclin and its Analogues in the Treatment of Cardiovascular Disease," *Heart Disease*, 1999, 1:29-40.
- Gessler et al., "Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension," *Eur. Respir. J.*, 2001, 17, 14-19.
- Ghofrani et al., "Hypoxia- and non-hypoxia-related pulmonary Haraldsson et al., "Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance," *Chest*, 1998, 114, 780-786.
- Hoepfer et al., "A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary hypertension," *J. American College of Cardiology*, 2000, 35, 176-182.
- Hoepfer et al., "Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease," *Respiratory Medicine*, 1999, 93, 62-70.
- Hoepfer et al., "Long term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue," *New England Journal of Medicine*, 2000, 342, 1866-1870.
- Howarth, P.H., "Why particle size should affect clinical response to inhaled therapy," *Journal of Aerosol Medicine*, 2001, 14 Suppl. 1, S-27-S-34.
- Ichida et al., "Additive effects of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension," *American Journal of Cardiology*, 1997, 80, 662-664.
- Krause et al., "Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man," *Eur. J. Clin. Pharmacol.*, 1986, 30, 61-68.
- Lee et al., "Current strategies for pulmonary arterial hypertension," *J. Internal Medicine*, 2005, 258, 199-215.
- Martin, John C., "Inhaled Form of Remodulin in the Pipeline," [http://www.phneighborhood.com/content/in\\_the\\_news/archive\\_2320.aspx](http://www.phneighborhood.com/content/in_the_news/archive_2320.aspx), ph Neighborhood, Oct. 28, 2005, 2 pages.
- Max et al., "Inhaled prostacyclin in the treatment of pulmonary hypertension," *Eur. J. Pediatr.*, 1999, 158 Suppl 1, S23-S26.
- Nebu-Tec med. Produkte Eike Kern GmbH, VENTA-NEB®-ir A-I-C-1® Operating Instructions, Sep. 2005.
- Olschewski et al. for the German PPH Study Group, "Inhaled iloprost to treat severe pulmonary hypertension—An uncontrolled trial," *Annals of Internal Medicine*, 2000, 132, 435-443.
- Olschewski et al., "Aerosolized prostacyclin and iloprost in severe pulmonary hypertension," *Annals of Internal Medicine*, 1996, 124, 820-824.
- Olschewski et al., "Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis," *Am. Respir. Crit. Care Med.*, 1999, 160, 600-607.
- Olschewski et al., "Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension," *Chest*, 2003, 124, 1294-1304.
- Olschewski et al., "Prostacyclin and its analogues in the treatment of pulmonary hypertension," *Pharmacology and Therapeutics*, 2004, 102, 139-153.
- Olschewski et al., "Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost," *Intensive Care Med.*, 1998, 24, 631-634.
- Pappert et al., "Aerosolized Prostacyclin Versus Inhaled Nitric Oxide in Children with Severe Acute Respiratory Distress Syndrome," *Anesthesiology*, Jun. 1995, 82(6):1507-1511.
- Rigby, Jonathan, Aradigm Corporation, "Technological advances for success: Product pipeline in targeted pulmonary delivery;" *Pulmonary Delivery Innovative Technologies Breathing New Life into Inhalable Therapeutics*, ONdrugDelivery, <http://www.ondrugdelivery.com/publications/Pulmonary.pdf>, 2006, 17-19.
- Sandifer et al., "Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation," *J. Appl. Physiol.*, 2005, 99:2363-2368.
- Santak et al., "Prostacyclin aerosol in an infant with pulmonary hypertension," *Eur. J. Pediatr.*, 1995, 154, 233-235.
- Soditt et al., "Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn," *Intensive Care Med.*, 1997, 23, 1275-1278.
- Steffen et al., "The Effects of 15AU81, a Chemically Stable Prostacyclin Analog, on the Cardiovascular and Renin-Angiotensin Systems of Anesthetized Dogs," *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 1991, 43:277-286.
- Stricker et al., "Sustained improvement of performance and haemodynamics with long-term aerosolized prostacyclin therapy in

(56)

**References Cited**

## OTHER PUBLICATIONS

Van Heerden et al., "Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypertension," *Anaesthesia and Intensive Care*, 1996, 24, 87-90.

Van Heerden et al., "Re: Delivery of inhaled aerosolized prostacyclin (IAP)," *Anaesthesia and Intensive Care*, 1996, 24, 624-625.

Voswinckel et al., "Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension," *Pulmonary Pharmacology & Therapeutics*, 2008, 21, 824-832.

Voswinckel et al., "Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension," *Journal of the American College of Cardiology*, 2006, 48(8):1672-1681.

Voswinckel et al., "Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension," *Annals of Internal Medicine*, Jan. 17, 2006, 144(2):149-150.

Walrath et al., "Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension," *Eur. Respir. J.*, 1997, 10, 1084-1092.

Wasserman et al., "Bronchodilator effects of prostacyclin (PGI<sub>2</sub>) in dogs and guinea pigs," *European Journal of Pharmacology*, 1980, 66, 53-63.

Webb et al., "The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism," *Intensive Care Med.*, 1996, 22, 353-355.

Wensel et al., "Effects of iloprost inhalation on exercise capacity and ventilator efficiency in patients with primary pulmonary hypertension," *Circulation*, 2000, 101, 2388-2392.

Wetzel, R.C., "Aerosolized prostacyclin: in search of the ideal pulmonary vasodilator," *Anesthesiology*, 1995, 82, 1315-1317.

Zanen et al., "Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction," *Thorax*, 1996, 51, 977-980.

Zanen et al., "The optimal particle size for beta-adrenergic aerosols in mild asthmatics," *International Journal of Pharmaceutics*, 1994, 107, 211-217.

Findlay et al., "Radioimmunoassay for the Chemical Stable Prostacyclin Analog, 15AU81: a Preliminary Pharmacokinetics Study in the Dog," *Prostaglandins Leukot. Essent. Fatty Acids*, Feb. 1993, 48(2):167-174.

McNulty et al., "The Pharmacokinetics and Pharmacodynamics of the Prostacyclin Analog 15AU81 in the Anesthetized Beagle Dog," *Prostaglandins Leukot. Essent. Fatty Acids*, Feb. 1993, 48(2):159-166.

Saini et al., "Effect of Electrostatic Charge and Size Distributions on Respirable Aerosol Deposition in Lung Model," *Industry Applications Conference, 2004, 39<sup>th</sup> IAS Annual Meeting, Conference Record of the 2004 IEEE Seattle, WA, Oct. 3-7, 2004*, 2:948-952.

Wittwer et al., "Inhalative Pre-Treatment of Donor Lungs Using the Aerosolized Prostacyclin Analog Iliprost Ameliorates Reperfusion Injury," *J. Heart Lung Transplant*, 2005, 24:1673-1679.

Agnew JE, Bateman RM, Pavia D, Clarke SW. (1984) Radionuclide demonstration of ventilatory abnormalities in mild asthma. *Clinical Science*; 66: 525-531.

*Annals of the International Commission on Radiological Protection (ICRP) vol. 28, No. 3, 1998, Publication 80, Radiation Dose to Patients from Radiopharmaceuticals.*

Blanchard, J.D., Cipolla, D., Liu, K., Morishige, R., Mudumba, S., Thippawong, J., Taylor, G., Warren, S., Radhakrishnan, R., Van Vlasselaer, R., Visor, G. and Starko, K. (2003) Lung Deposition of Interferon Gamma-1b following Inhalation via AERx® System vs. Respigard II™ Nebulizer Proc. ATS Annual Meeting (Abstract A373), Seattle.

Boyd, B., Noymer, P., Liu, K., Okikawa, J., Hasegawa, D., Warren, S., Taylor, G., Ferguson, E., Schuster, J., Farr, S., and Gonda, I. (2004) Effect of Gender and Device Mouthpiece Shape on Bolus Insulin Aerosol Delivery Using the AERx Pulmonary Delivery System. *Pharmaceutical Research*. 21 (10) 1776-1782.

Colthorpe P, Taylor G, Farr SJ. (1997) A comparison of two non-invasive methods for quantifying aerosol deposition in the lungs of rabbits. *J. Aerosol Med.*; 10:255.

Farr et al., "Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler," *International Journal of Pharmaceutics*, 2000, 198:63-70.

Miller et al., "Standardisation of spirometry. Series ATS/ERS Task Force: Standardisation of Lung Function Testing" *Eur Respir J* 2005; 26: 319-338.

National Radiological Protection Board. Doses to Patients from Medical Radiological Examinations in Great Britain. (1986) *Radiological Protection Bulletin No. 77.*

Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. Administration of Radioactive Substances Advisory Committee (ARSAC) (Mar. 2006). ARSAC Secretariat, Chilton, Didcot, Oxon. OX11 0RQ.

Publications of the International Commission on Radiological Protection (ICRP) (1977) *Recommendations of the International Commission on Radiological Protection 26.*

*Pulmonary Delivery, ONdrugDelivery*, 2006, 5 pages.

Final Office Action dated Oct. 10, 2014 in U.S. Appl. No. 12/591,200. Non-Final Office Action dated Mar. 9, 2014 in U.S. Appl. No. 12/591,200.

Final Office Action dated Oct. 17, 2012 in U.S. Appl. No. 12/591,200. Final Office Action dated Dec. 22, 2011 in U.S. Appl. No. 12/591,200.

Non-Final Office Action dated Jan. 29, 2015 in U.S. Appl. No. 13/120,015.

Final Office Action dated Jul. 2, 2013 in U.S. Appl. No. 13/120,015. Non-Final Office Action dated Oct. 31, 2012 in U.S. Appl. No. 13/120,015.

Non-Final Office Action dated Dec. 30, 2014 in U.S. Appl. No. 12/303,877.

Final Office Action dated Nov. 4, 2013 in U.S. Appl. No. 12/303,877. Non-Final Office Action dated Mar. 15, 2013 in U.S. Appl. No. 12/303,877.

Final Office Action dated Aug. 1, 2012 in U.S. Appl. No. 12/303,877. Non-Final Office Action dated Oct. 11, 2011 in U.S. Appl. No. 12/303,877.

Scientific discussion for the approval of Ventavis, European Medicines Agency (EMA), Oct. 20, 2004, 30 pages.

\* cited by examiner

FIGURE 1





FIGURE 2



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.